Ipamorelin, the First Selective Growth Hormone Secretagogue
Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH
European Journal of Endocrinology · Vol. 139(5) · pp. 552–561 · 1998
Landmark study establishing Ipamorelin as the first highly selective growth hormone secretagogue. Unlike other GHRPs, Ipamorelin stimulates GH release without significantly elevating cortisol, prolactin, or ACTH. This selectivity profile makes it the preferred GHRP for long-term use with minimal side effects.
Key Findings
Ipamorelin produces robust GH release comparable to GHRP-6 and GHRP-2
No significant elevation of cortisol, prolactin, or ACTH at therapeutic doses
Highly selective for GH secretion via ghrelin receptor pathway
Dose-dependent GH response with rapid onset and short duration
Synergistic effect when combined with GHRH analogs like CJC-1295
Methodology
Comparative in vivo study in rats and pigs measuring GH, cortisol, prolactin, and ACTH responses to Ipamorelin versus other GHRPs. Includes dose-response characterization.
Limitations
Animal model data; human pharmacodynamic studies limited. Long-term safety data not established.
Protocols Using This Research
Tags
Educational use only. Research summaries are provided for informational purposes. Always consult the original publication and a qualified healthcare provider before making clinical decisions.
Related Research
Build a protocol around this research
Our AI Advisor incorporates the latest research to build a personalized peptide protocol for your goals.
Start Assessment